RXRX实时信号 | 通过Getagraph.com最大化利润

出售 3705 min ago

@ $8.06

发出时间: 27 Apr 2024 @ 03:51

回报率: 0.74%

上一信号: Apr 27 - 02:19

上一信号: 购买

回报率: 0.94 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	4.39M
平均成交量	6.38M
市值	1.87B
EPS	$0 ( 2024-02-26 )
下一个收益日期	( $-0.430 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.14
ATR14	$0.459 (5.66%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Khan Najat	Buy	0
2024-04-16	Borgeson Blake	Sell	11 447	Class A Common Stock
2024-04-17	Secora Michael	Buy	37 500	Class A Common Stock
2024-04-16	Secora Michael	Buy	37 500	Class A Common Stock
2024-04-17	Secora Michael	Sell	23 124	Class A Common Stock

INSIDER POWER
39.70
Last 99 transactions
Buy: 2 818 975 \| Sell: 1 171 582

音量相关性

長: 0.47 (neutral)

短: -0.78 (moderate negative)

Signal:(71) Neutral

Recursion 相关性

10 最正相关
PLXP	0.893
LUMO	0.879
VIRX	0.876
FATE	0.874
STRC	0.867
HOOK	0.859
GROM	0.859
CLEU	0.857
SNCE	0.851
QTEK	0.85

10 最负相关
XOMAO	-0.832
CCRC	-0.827
XOMAP	-0.825
LUNA	-0.824
ITMR	-0.821
LRFC	-0.821
ACAHU	-0.814
AVEO	-0.813
MICT	-0.813
BNIXU	-0.811

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Recursion 相关性 - 货币/商品

0.24
( neutral )

0.46
( neutral )

0.00
( neutral )

0.25
( neutral )

-0.32
( neutral )

-0.11
( neutral )

Recursion 财务报表

Annual	2023
营收:	$44.58M
毛利润:	$-6.51M (-14.61 %)
EPS:	$-1.580

FY	2023
营收:	$44.58M
毛利润:	$-6.51M (-14.61 %)
EPS:	$-1.580

FY	2022
营收:	$39.68M
毛利润:	$-8.59M (-21.66 %)
EPS:	$-1.360

FY	2021
营收:	$10.18M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.658

Financial Reports:

No articles found.

Recursion

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.